INTRODUCTION
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) is the largest randomized trial ever conducted to compare antihypertensive medications (1) .
Sponsored by the US National, Heart, Lung, and Blood Institute in conjunction with the US Department of Veterans' Affairs, ALLHAT was designed to compare the efficacy of 4 types of antihypertensive medications -chlorthalidone (a thiazide-type diuretic), amlodipine (a calcium channel blocker [CCB] ), lisinopril (an angiontensin-converting enzyme [ACE] inhibitor) and doxazosin (an α-adrenergic blocker) -for reduction of risk of coronary heart disease (CHD) or other cardiovascular events (1) .
The first patients were enrolled in February 1994, and follow-up was scheduled until March 2002 (2) . In early 2000, the study investigators discontinued the α-adrenergic blocker arm because of an apparent increased risk of combined cardiovascular events among those receiving doxazosin as compared to those receiving chlorthalidone (2) . The main ALLHAT results, published in December 2002, showed that chlorthalidone was superior in preventing one or more major forms of cardiovascular disease and the investigators recommended that thiazide-type diuretics be the first line pharmacotherapy in the treatment of hypertension and, because many patients with hypertension require treatment with more than one antihypertensive, that thiazidetype diuretics generally be included in any therapeutic regimen for the treatment of hypertension (2) .
The primary outcome of ALLHAT was a combined endpoint of fatal congestive heart failure and nonfatal myocardial infarction and secondary outcomes included all-cause mortality, stroke, combined congestive heart failure, and combined cardiovascular disease. Despite limitations (3), the ALLHAT trial has had profound implications by shaping and bolstering clinical practice guidelines (4, 5) . Several studies in the US and Canada even suggest that the ALLHAT results have had a significant impact on clinical practice since considerable increases in use of thiazide-type diuretics immediately following ALLHAT publication have been observed in these countries (6,7).
Although results from North America are promising, Fretheim and Oxman have documented significant variations in antihypertensive prescribing between countries in general (8) . To date, little is known about trends in antihypertensive prescribing patterns in Italy following the ALLHAT publication. Thus, the objective of this study was to assess the impact the ALLHAT publication on antihypertensive prescribing patterns in Regione Emilia-Romagna (RER), Italy.
METHODS

Data Source and Study Population
We used outpatient prescription drug data from the RER administrative healthcare database, which has been described elsewhere (9, 10 
Analysis
The number of all antihypertensive prescriptions and new antihypertensive prescriptions for each study month was determined. The relative percentage of each antihypertensive class as a proportion of all antihypertensives or all new antihypertensives prescribed was computed for each study month. Using the data from the period preceding the ALLHAT publication (January 2000 to December 2002), we conducted time series analyses using stepwise autoregressive forecasting models (7) . In doing so, we estimated the predicted percentages and corresponding 95% CI for each antihypertensive class for the 12 months following the ALLHAT publication 
All Antihypertensive Prescriptions
No differences in overall prescribing patterns were observed for thiazide-type diuretics or Because this study was conducted in only one region, caution should be used when extrapolating the results to the rest of Italy. However, RER is a large region and we believe that prescribing patterns in RER likely reflect general prescribing attitudes throughout the country.
The lack of a significant change in prescribing patterns in Italy is in stark contrast to findings in some other countries. Following ALLHAT's publication, Austin and colleagues found sharp changes in prescribing patterns of antihypertensive medications in Ontario, Canada (6).
Consistent with the ALLHAT findings, these investigators observed a significant increase in new users of thiazide-type diuretics immediate following the ALLHAT publication and a significant decrease in new users of ACE-inhibitors and ARBs. Similarly, using US-based prescription drug data, Xie and colleagues found a significant increase in use of thiazide-type diuretics immediately following ALLHAT publication (7) . Several other studies have corroborated these findings in these countries, at least in the short-term (11) (12) (13) (14) . However, our study suggests that, unlike in North America, ALLHAT has had little or no impact on antihypertensive prescribing trends in Italy. Similarly, Kabir and colleagues observed no difference in prescribing of thiazidetype diuretics in Ireland (15) .
Explanations for this apparent dichotomy in the impact of ALLHAT results on antihypertensive prescribing in North American versus European countries can be postulated. Fretheim and Oxman suggest that international variation in antihypertensive prescribing may be explained largely by differences in drug promotion practices (8) . Furthermore, many potential barriers to adoption of clinical evidence and clinical practice guidelines may exist, including lack of awareness, lack of agreement, inertia of previous practice, as well as a number of external barriers (16) . In addition, in Italy, drugs deemed clinically important, such as antihypertensives, are available to patients virtually free of charge. Thus, financial incentives both for patients and physicians to manage hypertension with old, low-cost diuretics, as opposed to newer and often more expensive antihypertensives, are lacking and may contribute to inertia in clinical evidence adoption. Causes of the reluctance in changing of prescribing habits and patterns are likely multifactorial and complex. Nevertheless, the extent to which specific barriers to adoption of evidence-based medication prescribing affect some countries more than others is not known and warrants future research.
Arguments that, because ALLHAT was conducted in North America and published in an English-language journal, the results are not directly applicable to non-English speaking physicians in Italy, are feeble, at best. Large clinical trials, such as ALLHAT, generally yield results with biological implications applicable to many populations since biological mechanisms are ubiquitous regardless of the country in which one lives or the language that one speaks.
Clinical evidence must transcend geographical boundaries and its adoption must not be impeded by language barriers.
Furthermore, arguments that, because of differences in population characteristics and baseline prescribing patterns, the new clinical evidence produced by the ALLHAT study should not have an impact on antihypertensive prescribing patterns in RER rest on the notion that prescribing practices are, or are close to, optimal, such that the development and implementation of new clinical evidence would have only marginal effects on current prescribing trends. However, antihypertensive prescribing is suboptimal in RER given the relatively low rates of prescribing of thiazide-type drugs found in this study and also when comparing thiazide-type prescribing rates in this study to the findings of Xie et al in the US (7).
Indeed, Poluzzi and colleagues found that prior to ALLHAT publication, choice of initial drug treatment of hypertension among residents of RER did not accord with any major clinical guidelines (17) . We have also previously found evidence of potentially suboptimal drug prescribing practices in RER in other contexts (18) (19) (20) . Strategies to promote more appropriate medication prescribing and use in accordance with medical evidence and clinical guidelines are needed in Italy.
Academic detailing programs can be effective in reducing suboptimal drug use (21, 22) . Changes in reimbursement criteria to reflect evidence-based guidelines may also help improve prescribing patterns and promote evidence-based care (23) . Design of incentive-based programs should consider not only the prospective gain in health outcomes, but also the associated cost savings.
Fischer and Avorn found that adherence to evidence-based prescribing guidelines for hypertension alone could result in enormous savings to health systems (24) .
The results of this study should be interpreted with the following limitations in mind. First, this study utilized time series analysis which is useful as a quasi-experimental design to evaluate the influence of policies and other interventions on various measures of health resource utilization (25) . Such methods have been used widely in the study of outcomes associated with changes in and implementation of laws, programs, clinical guidelines, and health insurance and cost sharing policies in various countries (6, 7, 13, 15, (26) (27) (28) . Nevertheless, causal inference from time series analysis should proceed with caution (29) , particularly since drug prescribing patterns may be influenced by many factors independent of a particular intervention. For example, educational programs aimed at improving antihypertensive prescribing, changes in guidelines for the treatment of hypertension, and myriad policy changes could all affect prescribing patterns during the period of interest. However, to the best of our knowledge, no major changes that could have significantly affected antihypertensive medication prescribing and use occurred in RER during the study period. Examination of the study data further supports this notion since no observable major slope or level changes occurred in prescribing trends for any class of antihypertensive medications during the study period.
This study was designed to examine only the immediate impact on antihypertensive prescribing patterns in the year following ALLHAT publication and provides little information about longerterm changes in prescribing patterns beyond one year. Indeed, evidence of considerable lag times in physician adoption of evidence-based guidelines and research findings have been observed in certain contexts (30) . However, several studies have demonstrated that physicians in some countries rapidly changed prescribing behaviors immediately after ALLHAT publication and that these changes were observable within the first year or less following publication, suggesting that a one-year window is sufficient to detect immediate changes in prescribing patterns (6, 7, (11) (12) (13) .
Another limitation is that many of the antihypertensive medications included in this study are used frequently for other indications. Because of the nature of the prescription data, we were unable to link individual prescription records to their indications for use. Thus, we included all antihypertensive medications (except for combination products) which inevitably included prescriptions intended for uses other than hypertension. It is possible that this may have slightly diluted a true effect that the ALLHAT results may have had on prescribing patterns. However, other studies which were subject to this same limitation still observed an impact of ALLHAT on prescribing patterns despite any dilution of the effect (6,7). Thus, any dilution of the data in our study is not likely to have substantially affected our results. Finally, no adjustments for multiple testing were made in this study so results of statistical comparisons should be interpreted with care.
CONCLUSION
We found little evidence that the ALLHAT study had an impact on antihypertensive prescribing patterns in RER in the year following their publication. Use of thiazide-type diuretics was modestly increased after ALLHAT publication, but reached statistical significance for only one out of the 12 months of follow-up. A better understanding of unresponsiveness to clinical evidence in Italy is needed, particularly as it pertains to changes in prescribing patterns.
Programs that target evidence-based education or tie financial incentives to evidence-based prescribing practices may be warranted. 
